Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review.
Miles D, Zielinski C, Martin M, Vrdoljak E, Robert N.
Eur J Cancer. 2012 Mar;48(4):482-91. Epub 2012 Jan 16. Review.
Related citations
Scoring to predict the possibility of upgrades to malignancy in atypical ductal hyperplasia diagnosed by an 11-gauge vacuum-assisted biopsy device: an external validation study.
Bendifallah S, Defert S, Chabbert-Buffet N, Maurin N, Chopier J, Antoine M, Bezu C, Touche D, Uzan S, Graesslin O, Rouzier R.
Eur J Cancer. 2012 Jan;48(1):30-6. Epub 2011 Nov 17.
Safety of bevacizumab in metastatic breast cancer patients undergoing surgery.
Cortés J, Caralt M, Delaloge S, Cortes-Funes H, Pierga JY, Pritchard KI, Bollag DT, Miles DW.
Eur J Cancer. 2012 Mar;48(4):475-81. Epub 2011 Dec 22.
The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase.
Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Veer LV, Rubio IT, Viale G, Thompson AM, Passalacqua R, Nitz U, Vindevoghel A, Pierga JY, Ravdin PM, Werutsky G, Cardoso F.
Eur J Cancer. 2011 Dec;47(18):2742-9. Epub 2011 Nov 1.
The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials.
Yan T, Yin W, Zhou Q, Zhou L, Jiang Y, Du Y, Shao Z, Lu J.
Eur J Cancer. 2012 Jan;48(2):187-95. Epub 2011 Nov 17. Review.
Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer.
Wang X, Su L, Ou Q.
Eur J Cancer. 2012 May;48(8):1227-34. Epub 2011 Nov 5.
Systematic analysis of in vitro chemosensitivity and mib-1 expression in molecular breast cancer subtypes.
Liedtke C, Packeisen J, Hess KR, Vogt U, Kiesel L, Kersting C, Korsching E, Brandt B, Buerger H.
Eur J Cancer. 2011 Sep 13. [Epub ahead of print]
Physical activity in a German breast cancer patient cohort: one-year trends and characteristics associated with change in activity level.
Huy C, Schmidt ME, Vrieling A, Chang-Claude J, Steindorf K.
Eur J Cancer. 2012 Feb;48(3):297-304. Epub 2011 Sep 14.
Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Curtit E, Nouyrigat P, Dohollou N, Levy E, Lortholary A, Gligorov J, Facchini T, Jaubert D, Maille N, Pivot X, Grangé V, Cals L.
Eur J Cancer. 2011 Nov;47(16):2396-402. doi: 10.1016/j.ejca.2011.08.004. Epub 2011 Sep 13.
The role of surgery in metastatic breast cancer.
Ruiterkamp J, Ernst MF.
Eur J Cancer. 2011 Sep;47 Suppl 3:S6-22. Review.
Translational genomics in breast cancer.
Caldas C.
Eur J Cancer. 2011 Sep;47 Suppl 3:S381-2. Review. No abstract available.
The role of chemotherapy and targeted agents in patients with metastatic breast cancer.
Johnston SR.
Eur J Cancer. 2011 Sep;47 Suppl 3:S38-47. Review.
Triple negative breast cancer: a heterogeneous subgroup defined by what it is not.
Oakman C, Moretti E, Pacini G, Santarpia L, Di Leo A.
Eur J Cancer. 2011 Sep;47 Suppl 3:S370-2. Review. No abstract available.
Male breast cancer--neglected tumour.
Otto F.
Eur J Cancer. 2011 Sep;47 Suppl 3:S340-1. Review. No abstract available.
How to personalise treatment in early breast cancer.
Sørlie T.
Eur J Cancer. 2011 Sep;47 Suppl 3:S310-1. Review. No abstract available.
Breast cancer in the elderly: different treatment modalities.
Audisio RA.
Eur J Cancer. 2011 Sep;47 Suppl 3:S286-9. No abstract available.
Role of hormonal manipulations in patients with hormone-sensitive metastatic breast cancer.
Bodmer A, Castiglione-Gertsch M.
Eur J Cancer. 2011 Sep;47 Suppl 3:S28-37. Review. No abstract available.
Radiotherapy in patients with metastatic breast cancer.
Budach W.
Eur J Cancer. 2011 Sep;47 Suppl 3:S23-7. Review. No abstract available.
Breast cancer screening.
Autier P.
Eur J Cancer. 2011 Sep;47 Suppl 3:S133-46. Review. No abstract available.
Chairperson's introduction: Despite significant advances in the diagnosis and treatment of breast cancer, approximately one third of patients still develop, and subsequently die from metastatic breast disease.
Eur J Cancer. 2011 Sep;47 Suppl 3:S4-5. No abstract available.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on